Clinical Trial Update: Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) [Phase 1]

View source ↗

Summary

This is a Phase 1 trial (PRODIGY-2) evaluating personalized versus fixed-activity 177Lu-PSMA-617 radiopharmaceutical therapy for metastatic castration-resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (177Lu-PSMA-617) (lutetium-177 PSMA-617)

Snippet

Sponsor: Jean-Mathieu Beauregard | Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: RECRUITING